Department of Gastroenterology, Newcastle upon Tyne Hospitals NHS Foundation Trust, UK.
Clin Med (Lond). 2013 Aug;13(4):378-82. doi: 10.7861/clinmedicine.13-4-378.
The pathogenesis of inflammatory bowel disease (IBD) remains incompletely understood, but is thought to be a consequence of immune dysregulation, impaired mucosal integrity, enteric bacterial dysbiosis and genetic susceptibility factors. Recent drug advances in the treatment of IBD have clarified the role of existing medication, including 5-amino-salicylic acids (5-ASAs) and has seen a burgeoning use of treatment with biologicals. With recent advances in our understanding of these debilitating diseases, it is hoped that novel therapeutic targets can be identified.
炎症性肠病（IBD）的发病机制尚不完全清楚，但被认为是免疫失调、粘膜完整性受损、肠道细菌失调和遗传易感性因素的结果。最近在治疗 IBD 的药物方面的进展阐明了现有药物（包括 5-氨基水杨酸（5-ASA））的作用，并看到了生物制剂治疗的广泛应用。随着我们对这些使人衰弱的疾病的理解的最新进展，人们希望能确定新的治疗靶点。
